Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.55 |
| ▸ | NEK2 | P51955 | 4/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1668959 | 0.98 | HSD17B10 (0.65) | HSD17B10HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL16695496 | 0.91 | HSD17B10 (0.60) | HSD17B10HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL11994540 | 0.86 | HPGD (0.63) | HSD17B10HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL1989546 | 0.86 | HPGD (0.63) | HSD17B10HPGDHTTALDH1A1GRM5 | |
| Lithium Ion SCHEMBL1668957 | 0.84 | HPGD (0.61) | HSD17B10HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL28007419 | 0.83 | HSD17B10 (0.69) | HSD17B10HPGDHTTALDH1A1SLC6A7 | |
| SCHEMBL7234810 | 0.82 | KDM4C (0.53) | HSD17B10HPGDHTTKDM4ECYP2C19 | |
| SCHEMBL1667435 | 0.82 | HPGD (0.59) | HSD17B10HPGDHTTALDH1A1KDM4C | |
| SCHEMBL11996777 | 0.82 | HPGD (0.59) | HSD17B10HPGDHTTALDH1A1KDM4C | |
| SCHEMBL1700325 | 0.82 | HPGD (0.62) | HSD17B10HPGDHTTKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | claimed |
| US-8658651-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-25 | — | — | US | disclosed |
| EP-2512246-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| WO-2011075560-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010015652-A2 | THIAZOLE COMPOUNDS AS ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | HSD17B10 1730/4885HPGD 1122/4885HTT 4830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.